These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 10825141

  • 1. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
    Omer CA, Chen Z, Diehl RE, Conner MW, Chen HY, Trumbauer ME, Gopal-Truter S, Seeburger G, Bhimnathwala H, Abrams MT, Davide JP, Ellis MS, Gibbs JB, Greenberg I, Koblan KS, Kral AM, Liu D, Lobell RB, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Senderak ET, Oliff A, Kohl NE.
    Cancer Res; 2000 May 15; 60(10):2680-8. PubMed ID: 10825141
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 3. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
    Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL.
    Clin Cancer Res; 1999 Jan 15; 5(1):35-42. PubMed ID: 9918200
    [Abstract] [Full Text] [Related]

  • 4. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
    Mangues R, Corral T, Kohl NE, Symmans WF, Lu S, Malumbres M, Gibbs JB, Oliff A, Pellicer A.
    Cancer Res; 1998 Mar 15; 58(6):1253-9. PubMed ID: 9515813
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.
    Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM.
    Cancer Res; 1995 Nov 15; 55(22):5310-4. PubMed ID: 7585593
    [Abstract] [Full Text] [Related]

  • 6. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 15; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 7. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM, Lau N, Guha A.
    Oncogene; 1999 Dec 09; 18(52):7514-26. PubMed ID: 10602510
    [Abstract] [Full Text] [Related]

  • 8. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K.
    Gan To Kagaku Ryoho; 1997 Sep 09; 24(11):1495-502. PubMed ID: 9309147
    [Abstract] [Full Text] [Related]

  • 9. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
    Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE, Koester SK, Troyer DA, Bearss DJ, Conner MW, Gibbs JB, Hamilton K, Koblan KS, Mosser SD, O'Neill TJ, Schaber MD, Senderak ET, Windle JJ, Oliff A, Kohl NE.
    Mol Cell Biol; 1998 Jan 09; 18(1):85-92. PubMed ID: 9418856
    [Abstract] [Full Text] [Related]

  • 10. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
    Anthony NJ, Gomez RP, Schaber MD, Mosser SD, Hamilton KA, O'Neil TJ, Koblan KS, Graham SL, Hartman GD, Shah D, Rands E, Kohl NE, Gibbs JB, Oliff AI.
    J Med Chem; 1999 Aug 26; 42(17):3356-68. PubMed ID: 10464022
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice.
    Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K.
    Nat Med; 1995 Aug 26; 1(8):792-7. PubMed ID: 7585182
    [Abstract] [Full Text] [Related]

  • 12. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Li Z, Dell J, Lipari P, Malkowski M, Prioli N, Rossman RR, Korfmacher WA, Nomeir AA, Lin CC, Mallams AK, Doll RJ, Catino JJ, Girijavallabhan VM, Kirschmeier P, Bishop WR.
    Cancer Chemother Pharmacol; 1999 Aug 26; 43(1):50-8. PubMed ID: 9923541
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 26; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 14. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K, Nagasu T.
    Gan To Kagaku Ryoho; 1997 Jan 26; 24(2):145-55. PubMed ID: 9030225
    [Abstract] [Full Text] [Related]

  • 15. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 16. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB, Silverman KC, Jayasuriya H, Kim BM, Amo SE, Wilson FR, Rew DJ, Schaber MD, Bergstrom JD, Koblan KS, Graham SL, Kohl NE, Gibbs JB, Singh SB.
    J Med Chem; 1998 Nov 05; 41(23):4492-501. PubMed ID: 9804689
    [Abstract] [Full Text] [Related]

  • 17. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Cancer Res; 1995 Oct 01; 55(19):4243-7. PubMed ID: 7671229
    [Abstract] [Full Text] [Related]

  • 18. [Farnesyl transferase inhibitors: one target may be found in another].
    Mazières J, Pradines A, Favre G.
    Med Sci (Paris); 2003 Feb 01; 19(2):211-6. PubMed ID: 12836615
    [Abstract] [Full Text] [Related]

  • 19. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA, Sigman CC.
    Cancer Epidemiol Biomarkers Prev; 1997 Apr 01; 6(4):267-82. PubMed ID: 9107432
    [Abstract] [Full Text] [Related]

  • 20. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J, Pradines A, Favre G.
    Cancer Lett; 2004 Apr 08; 206(2):159-67. PubMed ID: 15013521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.